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Abstract
 
Background.
 
Patients with acute myocardial
infarction who were treated with accelerated tissue plas-
minogen activator (t-PA) (given over a period of 1
 
1
 
⁄
 
2
 
 hours
rather than the conventional 3 hours, and with two thirds
of the dose given in the first 30 minutes) had a 30-day
mortality that was 15 percent lower than that of patients
treated with streptokinase in the Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Oc-
cluded Coronary Arteries (GUSTO) study. This was equiv-
alent to an absolute decrease of 1 percent in 30-day mor-
tality. We sought to assess whether the use of t-PA, as
compared with streptokinase, is cost effective.
 
Methods.
 
Our primary, or base-case, analysis of cost
effectiveness used data from the GUSTO study and life
expectancy projected on the basis of the records of sur-
vivors of myocardial infarction in the Duke Cardiovascular
Disease Database. In the primary analysis, we assumed
that there were no additional treatment costs due to the
use of t-PA after the first year and that the comparative
survival benefit of t-PA was still evident one year after en-
rollment.
 
Results.
 
One year after enrollment, patients who re-
ceived t-PA had both higher costs ($2,845) and a higher
survival rate (an increase of 1.1 percent, or 11 per 1000
patients treated) than streptokinase-treated patients. On
the basis of the projected life expectancy of each treat-
ment group, the incremental cost-effectiveness ratio —
with both future costs and benefits discounted at 5 percent
per year — was $32,678 per year of life saved. The use
of t-PA was least cost effective in younger patients and
most cost effective in older patients. At all ages, the use of
t-PA in patients with anterior infarctions yielded more fa-
vorable cost-effectiveness values. In our secondary anal-
yses, the cost-effectiveness values were most sensitive to
a lowering of the projected long-term survival benefits of
t-PA and to moderate or greater increases in the projected
medical costs for patients in the t-PA group after the first
year. In contrast, our results were not sensitive to even
very unfavorable assumptions about the additional costs
associated with the higher rate of disabling stroke that was
noted in patients treated with t-PA in the GUSTO study.
 
Conclusions.
 
The cost effectiveness of treatment with
accelerated t-PA rather than streptokinase compares fa-
vorably with that of other therapies whose added medical
benefit for dollars spent is judged by society to be worth-
while. (N Engl J Med 1995;332:1418-24.)
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T
 
HE value of thrombolytic therapy for patients with
acute myocardial infarction has been firmly es-
tablished. To identify the thrombolytic approach that
most effectively produces sustained patency of the in-
farct-related artery and improves survival, the Global
Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries (GUSTO)
investigators compared four different regimens: accel-
erated tissue plasminogen activator (t-PA), streptoki-
nase with intravenous heparin, streptokinase with sub-
cutaneous heparin, and a combination of t-PA and
streptokinase.
 
1 
 
(“Accelerated” refers to the administra-
tion of t-PA over a period of 1
 
1
 
⁄
 
2
 
 hours — with two
thirds of the dose given in the first 30 minutes — rather
than the conventional period of 3 hours.) That study
found a statistically significant relative decrease of 15
percent and an absolute decrease of 1 percent in 30-day
mortality from all causes for treatment with accelerated
t-PA as compared with the pooled streptokinase regi-
mens (the mortality rates for which were not signifi-
cantly different from one another). Furthermore, t-PA
reduced the risk of death in each of the analyzed sub-
groups.
 
1
 
 Some observers have questioned whether the
improved survival rates seen in the GUSTO study are
worth the substantial additional cost of t-PA.
We conducted a cost-effectiveness analysis to com-
pare the value of t-PA treatment with that of streptoki-
nase treatment on the basis of the information on mor-
tality and use of resources from the GUSTO study and
detailed data on the use of medical resources and the
quality of life of a random subgroup of the GUSTO co-
hort residing in the United States.
 
M
 
ETHODS
 
Our analysis comparing accelerated t-PA with streptokinase used
data from the GUSTO study: data on 1-year survival for all 41,021
patients enrolled in the study, data on the use of medical resources
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during the initial hospitalization for all 23,105 U.S. patients, and data
on a prospective random sample of 2600 U.S. patients who under-
went structured interviews by telephone 30 days, 6 months, and 12
months after enrollment on their use of medical resources and qual-
ity of life.
 
1,2
 
 The particular costs and benefits examined in a cost-
effectiveness analysis vary with the perspective of the study.
 
3,4
 
 In
medical economics, the analysis can be constructed to reflect the
viewpoint of society as a whole, payers, health care providers, or pa-
tients. In the present study, we used a social perspective to identify
relevant costs, although indirect costs (e.g., time lost from work) and
nonmedical costs were not included. Effectiveness was measured in
terms of additional life expectancy, and the effects of the treatments
on the patients’ quality of life were examined in a sensitivity analy-
sis.
 
5,6
 
 Both survival and costs were discounted continuously at an an-
nual rate of 5 percent, as is consistent with conventional practice.
 
6,7
 
Extensive sensitivity analyses were performed. Cost-effectiveness ra-
tios were expressed as the additional lifetime costs required to add
one extra year of life with t-PA treatment as compared with strepto-
kinase therapy. Higher cost-effectiveness ratios indicate lower cost ef-
fectiveness.
 
Determining Costs
 
The costs of initial hospitalization (including charges for any trans-
fers between hospitals) were calculated in two ways: from total cost
estimates (variable costs plus fixed costs) from the Duke Transition
One cost-accounting system, and from Medicare diagnosis-related-
group (DRG) reimbursement rates (Table 1). The Transition One
system estimates hospital costs using a bottom-up approach that is
based on resources consumed and unit prices for those resources.
 
3
 
Costs of the thrombolytic agents were also calculated in two ways:
from the 
 
Drug Topics Red Book
 
 average of 1993 wholesale prices,
 
8
 
 and
from the average costs of the drugs in 16 randomly selected GUSTO
hospitals (2 hospitals in each GUSTO geographic region).
 
1
 
 The 
 
Red
Book 
 
average wholesale price of 1.5 million units of streptokinase was
$320; the price of 100 mg of t-PA was $2,750. The average cost to
the 16 GUSTO hospitals was $270 for 1.5 million units of streptoki-
nase and $2,216 for 100 mg of t-PA. We assumed that pharmacy han-
dling and preparation costs and drug-administration costs would be
equivalent for the two regimens. For follow-up hospitalization costs,
we used Medicare DRG reimbursement rates for North Carolina
(Table 1). Reported hospitalizations and revascularization proce-
dures were verified with the relevant institution. Physicians’ fees for
both initial and follow-up hospitalizations were drawn from the
Medicare fee schedule for North Carolina (Table 1).
For the primary analysis, incremental costs included only cumula-
tive hospital and physicians’ costs for the first year after treatment.
Because there were no empirical data on costs after one year, the pri-
mary analysis assumed no cost differences between the treatment
groups after one year. All costs were expressed in 1993 dollars.
 
Estimating Survival
 
To estimate survival rates after the end of follow-up in the GUSTO
study, the primary analysis assumed that the hazard of death after
one year did not depend on the thrombolytic agent received (i.e., that
the survival curves of the two treatment groups were parallel) and
that the patients’ pattern of long-term survival was typical of the
chronic, stable phase of coronary heart disease. To represent that
pattern, we constructed a Cox proportional-hazards model based on
the experience of 4379 patients in the Duke Cardiovascular Disease
Database
 
9-12
 
 with myocardial infarction between 1971 and 1992 who
had either pathologic Q waves on a resting 12-lead electrocardio-
gram or a marked focal wall-motion abnormality seen on a left ven-
triculogram and who survived at least one year. This survival model
was used to extend the 1-year survival data by an additional 14 years.
For the model, we selected covariates that were available in the
GUSTO data base, including age, sex, and location of infarction. Be-
cause, in the Duke data, approximately 20 percent of patients were
alive at the last follow-up, we used a Gompertz function to extrapo-
late the tail of the survival curve.
 
13
 
Using this composite modeling approach, we generated lifetime
survival curves for both treatment groups and calculated life expect-
ancy as the area under each curve. The increase in life expectancy
for the t-PA group was thus represented by the difference between
the areas under the two curves. The survival curve for the t-PA group
is presented in Figure 1.
 
Sensitivity Analyses
 
Extensive sensitivity analyses were performed in order to find
threshold values for variables in the model that would result in a cost-
effectiveness ratio of more than $50,000 per year of life saved. We
varied survival and costs in both the short and the long term for the
t-PA group, the costs and adverse health consequences of the in-
creased risk of disabling stroke associated with t-PA, and the utility
weights we used to reflect the attitude of patients toward their cur-
rent state of health.
 
Utility
 
Utility (a number from 0 to 100 that summarizes the value patients
attach to their current state of health) was measured in structured
telephone interviews one year after treatment. Patients were asked,
in a series of questions, how much of their current life expectancy —
assumed to be 10 years in their present state of health — they would
be willing to give up in order to live their remaining years in excellent
health.
 
14,15
 
Subgroup Analysis
 
We calculated the comparative cost-effectiveness value for treat-
ment with t-PA instead of streptokinase for eight clinical subgroups
defined by the patient’s age (up to 40 years, 41 to 60 years, 61 to 75
 
*Data on hospital costs are from the Duke Transition One cost-accounting system. Physicians’
fees are from the Medicare fee schedule for North Carolina. ICU denotes intensive care unit.
†Costs shown are for procedures only.
‡Data on hospital costs are Medicare diagnosis-related-group (DRG) reimbursement rates
for North Carolina; the DRG codes are shown in parentheses. Physicians’ fees are from the
Medicare fee schedule for North Carolina.
 
Table 1. Costs Used in the Analysis.
 
I
 
TEM
 
H
 
OSPITAL
 
C
 
OST
 
P
 
HYSICIANS
 
’
F
 
EES
 
dollars
 
Initial hospitalization
 
*
Day in ICU, no complications 1,380 126
Day in ICU, mild-to-moderate complications 2,070 187
Day in ICU, severe complications 2,760 248
Hospital day, not in ICU 475 54
Diagnostic cardiac catheterization† 1,670 400
Coronary angioplasty† 6,200 1,356
Coronary bypass surgery† 8,800 2,564
Use of intraaortic balloon pump 824 538
Use of temporary pacemaker 562 209
Pulmonary-artery catheterization 270 303
Cardioversion–defibrillation 112 134
Interhospital transfer 970 —
Emergency department visit 300 116
 
Rehospitalization
 
‡
Coronary bypass surgery with catheterization (106) 19,092
Coronary bypass surgery without catheterization (107) 14,121
Coronary angioplasty (112) 6,635
Acute myocardial infarction, complicated (121) 5,384
Fatal acute myocardial infarction (123) 4,745
Cardiac catheterization with complex diagnosis other than 
myocardial infarction (124)
4,137
Acute myocardial infarction, uncomplicated (122) 3,807
Heart failure and shock (127) 3,440
Cardiac catheterization without complex 
diagnosis (125)
2,676
Angina pectoris (140) 2,098
Chest pain (143) 1,744
Diagnostic cardiac catheterization 400
Coronary angioplasty 1,356
Coronary bypass surgery 2,823
Initial hospital day 111
Subsequent hospital day 54
Initial clinic visit 96
Subsequent clinic visit 45
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years, or more than 75 years) and the location of the infarction (an-
terior or inferior). In a linear regression analysis, neither age nor the
location of the infarction had an identifiable association with costs in
the first year after treatment. Consequently, we used the cost differ-
ences from our primary analysis in calculating the cost-effectiveness
values for the eight subgroups.
 
Statistical Analysis
 
Descriptive data are presented as percentages for discrete vari-
ables and as medians with 25th and 75th percentiles for continuous
variables (Table 2). Intention-to-treat analyses of base-line, six-
month, and one-year data were performed with a chi-square test for
discrete variables and by the Wilcoxon rank-sum test for continuous
variables.
 
R
 
ESULTS
 
Primary Analysis
 
Costs
 
Resource consumption within the first year was gen-
erally similar in the streptokinase and t-PA groups
(Table 2). There was a slightly higher use of pulmo-
nary-artery catheters in the patients who received
streptokinase during the initial hospitalization (20 per-
cent, vs. 18 percent in the t-PA group; P
 

 
0.002).
There was a trend toward more percutaneous translu-
minal coronary angioplasty in the t-PA group (3 per-
cent vs. 2 percent, P
 

 
0.03) and more rehospitalization
(19 percent vs. 15 percent, P
 

 
0.06) from six months to
one year after enrollment (Table 2). At the time of ini-
tial hospital discharge, there was no difference between
the two treatment groups in the rates of use of any
of the major classes of cardiac medications. The esti-
mated cumulative medical costs (hospital costs plus
physicians’ fees) at one year, exclusive of the cost
of the thrombolytic agent, averaged $24,575 for pa-
tients treated with streptokinase and $24,990 for pa-
tients treated with t-PA. When the 
 
Red Book
 
 drug costs
for the thrombolytic agent were added, the incremen-
tal, undiscounted costs for each patient who received
t-PA were $2,845. The primary analysis assumed no in-
creased costs for the t-PA group after the first year.
 
Life Expectancy
 
Survival at 30 days was 92.7 percent in the strepto-
kinase group and 93.7 percent in the t-PA group
(P
 

 
0.001), and 89.9 percent and 91.0 percent, respec-
tively, after one year (P
 

 
0.006). We projected a life ex-
pectancy from the time of enrollment in the GUSTO
study of 15.27 years for patients treated with streptoki-
nase and 15.41 years for patients treated with t-PA, or
an undiscounted increase in life expectancy for the
t-PA group of 0.14 year per patient (i.e., 14 additional
years of life per 100 patients treated with t-PA).
 
Cost Effectiveness
 
With an increased life expectancy in the t-PA group
of 0.14 year of life per patient, an increased cost of
 
Figure 1. Probability of Survival among Patients Treated 
with t-PA.
A survival function of this type was used to estimate life expect-
ancy for each treatment group. The curve consists of three parts:
the survival pattern in the first year after treatment in the GUSTO
study, data for an additional 14 years on survivors of myocardial
infarction in the Duke Cardiovascular Disease Database, and a
Gompertz parametric survival function adjusted to agree with the
empirical survival data at the 10-year and 15-year follow-up
points.
Pr
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*Data on the initial hospitalization are for all U.S. subjects in the GUSTO study who were
randomly assigned to t-PA or streptokinase. Data on the period from discharge to one year after
discharge are for the random sample of the surviving members of this cohort who were inter-
viewed by telephone at 30 days, 6 months, and 1 year. PTCA denotes percutaneous translumi-
nal coronary angioplasty, CABG coronary-artery bypass surgery, and ICU intensive care unit.
For cardiac catheterization and PTCA, percentages reflect the number of patients who had at
least one procedure. Values followed by a range in parentheses are medians with 25th and 75th
percentiles.
†The mean value for the t-PA group was 1.5 days, and that for the streptokinase group was
1.0 day.
 
Table 2. Use of Medical Resources during the Initial Hospitaliza-
tion and up to One Year after Discharge, According to
Treatment.
 
*
 
I
 
TEM
 
S
 
TREPTOKINASE
 
t-PA P V
 
ALUE
 
Initial hospitalization
 
No. of patients 11,310 5908
Cardiac catheterization (%) 72 73 0.51
PTCA (%) 31 31 0.86
CABG (%) 13 13 0.29
Pulmonary-artery catheterization (%) 20 18 0.002
Use of ventilator (%) 17 16 0.14
Use of intraaortic balloon pump (%) 6 6 0.21
Length of stay in ICU (days) 3.5 (2.5–5) 3.5 (2.5–5) 0.69
Total length of stay (days) 8 (6–11) 8 (6–11) 0.92
 
From discharge to 6 months
 
No. of patients 1,187 580
Cardiac catheterization (%) 14 17 0.26
PTCA (%) 10 12 0.41
CABG (%) 5 6 0.74
No. of rehospitalizations (%)
1
2
 

 
3
23
6
3
24
7
3
0.94
Hospital days 0 (0–2) 0 (0–2) 0.66
Total outpatient visits to physician
To cardiologist
To internist
To family or general practice physicians
To emergency department
5 (3–7)
2 (1–4)
0 (0–0)
1 (0–2)
0 (0–0)
5 (3–7)
2 (1–4)
0 (0–0)
1 (0–2)
0 (0–1)
0.99
0.43
0.05
0.60
0.26
 
From 6 months to 1 year after discharge
 
No. of patients 1,135 553
Cardiac catheterization (%) 5 5 0.73
PTCA (%) 2 3 0.03
CABG (%) 1 2 0.27
No. of rehospitalizations (%)
1
2
 

 
3
12
2
1
14
4
1
0.06
Follow-up hospital days† 0 (0–0) 0 (0–0) 0.03
Total outpatient visits to physician
To cardiologist
To internist
To family or general practice physicians
To emergency department
3 (2–5)
1 (0–2)
0 (0–0)
1 (0–2)
0 (0–0)
3 (2–5)
1 (0–2)
0 (0–0)
1 (0–2)
0 (0–0)
0.37
0.90
0.77
0.23
0.42
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$2,845 per patient, and a discount rate of 5 percent, the
comparative primary cost-effectiveness ratio for the use
of t-PA instead of streptokinase was $32,678 per year
of life saved. Substituting the average thrombolytic-
drug costs to the hospitals in the GUSTO study for the
 
Red Book 
 
wholesale prices in our primary analysis yield-
ed a cost-effectiveness value of $27,115 per year of life
saved. If we used Medicare DRG reimbursement rates
for the initial hospitalization rather than the Duke
Transition One costs, kept the 
 
Red Book 
 
prices for the
thrombolytic agents, and left all other factors un-
changed, the increase in costs for patients treated with
t-PA was $3,154 and the cost-effectiveness ratio be-
came $36,218 per year of life saved. Substituting the
GUSTO prices for thrombolytic agents into this latter
calculation reduced the additional cost of t-PA treat-
ment to $2,670 and lowered the cost-effectiveness value
to $30,655 per year of life saved.
 
Sensitivity Analyses
 
Differences in One-Year Survival
 
The 95 percent confidence interval for the 1.1 per-
cent increase in one-year survival among patients in
the t-PA group was 0.46 percent to 1.74 percent, a
range that would produce cost-effectiveness ratios of
$71,039 to $18,781 per year of life saved.
 
Differences in Long-Term Survival
 
The true life expectancy of the subjects could differ
from the value predicted in our model of approximately
15 years. In addition, the survival curves may actually
converge or diverge after one year. Either reducing the
life expectancy or causing the survival curves to con-
verge would reduce the additional years of life saved by
t-PA treatment (Fig. 2). With a 5 percent discount rate,
the cost-effectiveness ratio would rise above $50,000 if
the number of years of life saved by t-PA treatment fell
below 7 undiscounted years per 100 patients, and it
would rise above $100,000 per year of life saved if the
number of undiscounted years of life saved per 100 pa-
tients fell below 3.
Discounting the value of future costs and benefits re-
duces their present value. If costs and increased years
of life were not discounted at all, the primary cost-
effectiveness ratio in our study would be $20,468 per
year of life saved; if a discount rate of 10 percent was
used, however, the cost-effectiveness ratio would rise to
$47,337 per year of life saved.
 
Cost Differences in the First Year
 
Although the difference in associated costs between
streptokinase and t-PA (exclusive of the cost of the
drugs themselves) was not statistically significant, vari-
ations in the increased costs associated with t-PA treat-
ment did affect the cost-effectiveness ratio (Fig. 3). A
cost-effectiveness value of $50,000 is reached when the
additional cost of t-PA treatment, including the cost of
the thrombolytic agents, exceeds $4,350 per patient (53
percent higher than the cost calculated in the primary
analysis). If the additional cost of t-PA use were $2,000,
the cost-effectiveness ratio would be $27,736 per year
of life saved. If the drug costs were those typical in Eu-
rope (approximately $1,000 for 100 mg of t-PA and
$200 for 1.5 million units of streptokinase), the cost-
effectiveness ratio would be $13,943 per year of life
saved.
 
Cost Differences after One Year
 
In the primary analysis, we assumed no cost differ-
ence between t-PA and streptokinase beyond the first
year after treatment. In a random subgroup of U.S. pa-
tients, we observed a mean increased cost per patient
for the t-PA group between six months and one year of
$508 (P
 

 
0.38). Although it was not statistically signif-
 
Figure 2. Sensitivity Analysis of the Long-Term Increase in Sur-
vival in the t-PA Group as Compared with the Streptokinase
Group.
The y axis shows cost-effectiveness ratios expressed as dollars
per additional year of life saved (all values are discounted). The
x axis shows undiscounted years of life saved by the use of t-PA
per 100 patients treated. In the primary analysis, t-PA saved 14
additional years of life per 100 patients treated and had a cost-
effectiveness ratio of $32,678. If the t-PA and streptokinase sur-
vival curves converged over time, or if the life expectancy of the
GUSTO cohort was less than that projected in our analysis, then
the cost-effectiveness value would be greater and, therefore,
less favorable.
Co
st
-E
ffe
ct
ive
ne
ss
 R
at
io
(th
ou
sa
nd
s o
f d
oll
ars
)
140
120
100
80
60
40
20
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Years of Life Saved per 100 Patients
Treated with t-PA
 
Figure 3. Sensitivity Analysis of the Cost Difference between
Treatment with t-PA and Treatment with Streptokinase, Assum-
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ing No Cost Differences beyond the First Year after Treatment.
The y axis shows cost-effectiveness ratios expressed as dollars
per additional year of life saved. The x axis shows the increased
cost per patient associated with treatment with t-PA. In the pri-
mary analysis, the increased cost per patient was $2,845.
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icant, we used this figure to estimate the possible in-
crease in long-term costs for subjects who survived one
year after treatment. If we annualize this figure to
$1,016 per year, discount future costs at 5 percent per
year, and calculate on the basis of the average GUSTO
patient’s life expectancy (15 years), an additional $9,975
is added to the costs associated with t-PA, yielding an
incremental cost-effectiveness ratio of $147,333 per
year of life saved. If the increased level of cost contin-
ues for only the second year after treatment, then the
cost-effectiveness ratio would be approximately $44,000.
If the higher costs continue through the third year of
follow-up, the cost-effectiveness ratio would be approx-
imately $55,300 per year of life saved.
 
Quality of Life
 
At one year, the mean utility weights measured in
our interviews were 0.90 for both treatment groups.
That is, patients were hypothetically willing to trade 10
years of life at their present state of health for 9 years
of excellent health. Weighting increased survival in
both groups by this factor yielded a cost-effectiveness
ratio of $36,402 per quality-adjusted year of life saved.
 
Increased Risk of Stroke
 
In the first 30 days after treatment in the GUSTO
study, t-PA produced a net increase of one disabling
nonfatal stroke per 1000 patients treated, as compared
with the rate with streptokinase.
 
1
 
 If disabling nonfatal
stroke is considered an end point equivalent to death in
the hospital, then the increase in life expectancy esti-
mated for the t-PA group in our model is reduced to
0.13 undiscounted year per patient, and the primary
cost-effectiveness ratio increases to $35,538.
Costs for the care of survivors of stroke in the first
year after treatment were included in our primary
analysis. In a sensitivity analysis, we assumed that pa-
tients with stroke who were in a rehabilitation hospital
or nursing home one year after treatment (12 percent
of the stroke survivors) would incur the costs of such
care (an average daily cost of $1,212 for care in a reha-
bilitation hospital and $155 for nursing home care) for
the remainder of their life expectancy. Allocating these
extra costs to the t-PA group on the basis of one addi-
tional disabling nonfatal stroke per 1000 patients, and
counting disabling stroke as an end point equivalent to
death in the hospital, produce a cost-effectiveness ratio
of $36,238. If each additional disabling stroke in the
t-PA group required nursing home care for an average
of 15 years, then the cost-effectiveness ratio would be
$42,400.
 
Subgroup Analyses
 
We calculated incremental cost-effectiveness ratios
for eight clinical subgroups defined by age and location
of the infarction (Table 3). The number of years of life
added by treatment with t-PA was greater for older pa-
tients than for younger patients and greater for anterior
than for inferior infarction. For patients with anterior
myocardial infarction, cost-effectiveness ratios were
above $50,000 only for subjects 40 years of age or
younger. For patients with inferior myocardial infarc-
tion, values were above $50,000 for subjects up to 60
years of age.
 
D
 
ISCUSSION
 
The substitution of accelerated t-PA for streptoki-
nase in the treatment of acute myocardial infarction
yields increased health benefits at a cost comparable to
those of other expensive therapies routinely considered
worthwhile. Benchmarks against which the average
comparative cost-effectiveness ratio of t-PA ($32,678
per year of life saved) can be measured include that of
coronary bypass surgery as compared with medical
therapy for left main coronary artery disease ($7,000
per year of life saved), that of medical therapy as com-
pared with no therapy for severe hypertension ($20,000
per year of life saved), and that of hemodialysis as
compared with no dialysis for chronic renal failure
($35,000 per year of life saved).
 
16
 
 The upper limit for
an acceptable cost-effectiveness ratio remains contro-
versial, but values of more than $100,000 per year of
life saved are generally considered too high. Most pre-
vious economic analyses of thrombolytic therapy have
compared therapy with no therapy rather than compar-
ing different agents.
 
16-18
 
 Several earlier attempts to
examine the incremental cost effectiveness of t-PA
relative to streptokinase have made assumptions that
are inappropriate in the light of the findings of the
GUSTO study.
 
1,19,20
 
 However, Naylor et al. found that
treatment with t-PA was cost effective, providing that
the drug’s beneficial effect on survival, as compared
with streptokinase, was sustained for five years.
 
21
 
Sensitivity Analyses
 
Our sensitivity analysis examined the effects of alter-
ing the key assumptions of the cost-effectiveness anal-
ysis, such as our estimate of 14 years of life saved per
100 patients treated with t-PA. This estimate was based
 
*MI denotes myocardial infarction. All patients in each treatment group
were included in the primary analysis.
†Cost-effectiveness ratios show the cost in dollars per year of life saved
(both discounted at 5 percent); these calculations were based on the as-
sumption that patients treated with t-PA had costs in the first year that were
$2,845 higher than those for patients treated with streptokinase.
 
Table 3. Cost-Effectiveness Ratios for t-PA as Com-
pared with Streptokinase in the Primary Analysis
and for Selected Subgroups of Patients.
 
G
 
ROUP
 
 
 
OF
 
 P
 
ATIENTS
 
*
I
 
NCREASED
 
 L
 
IFE
 
E
 
XPECTANCY
WITH
 
 t-PA
C
 
OST
 
-E
 
FFEC-
TIVENESS
 
R
 
ATIO
 
†
 
UNDISCOUNTED DISCOUNTED
 
yr of life saved dollars
 
Primary analysis 0.14 0.09 32,678
Inferior MI, age 
 

 
40 0.03 0.01 203,071
Anterior MI, age 
 

 
40 0.04 0.02 123,609
Inferior MI, age 41–60 0.07 0.04 74,816
Anterior MI, age 41–60 0.10 0.06 49,877
Inferior MI, age 61–75 0.16 0.10 27,873
Anterior MI, age 61–75 0.20 0.14 20,601
Inferior MI, age 
 

 
75 0.26 0.17 16,246
Anterior MI, age 
 

 
75 0.29 0.21 13,410
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on our survival model, on the increase in one-year sur-
vival observed in patients treated with t-PA as com-
pared with those treated with streptokinase, and on an
assumption that the survival curves for the two treat-
ment groups would remain parallel after one year. The
assumption that the survival curves will remain paral-
lel is supported by the findings of other studies indi-
cating that the benefit of thrombolysis is sustained
through five years of follow-up.
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 In our sensitivity
analysis of the assumed increase in survival, a thresh-
old cost-effectiveness ratio of $50,000 per year of life
saved was not exceeded until the increased survival for
the t-PA group fell below 7 years of life added per 100
patients treated; a threshold value of $100,000 per year
of life saved was not reached until the added years of
life per 100 patients treated fell below 3.
Our results were not sensitive to changes in our esti-
mates of costs. Only when the assumed increase in
costs attributable to treatment with t-PA during the
first year was 1.5 times greater than the value used in
our study did the resulting cost-effectiveness ratio ex-
ceed $50,000 per year of life saved. If the patients who
received t-PA were assumed to have continuing ad-
ditional costs of about $1,100 per year (a figure project-
ed from the nonsignificant cost difference observed in
the second six months of follow-up) past the second
follow-up year, the cost-effectiveness ratio became
greater than $50,000. However, there is no basis in the
empirical data from the GUSTO study for expecting
such long-term cost differences between the two treat-
ments.
 
Importance of Disabling Strokes
 
One important question is the extent to which the
additional hemorrhagic strokes produced by t-PA may
cancel out some of the observed increase in survival,
thereby making t-PA less attractive and less cost effec-
tive.1 However, even the most unfavorable assumptions
about nonfatal disabling stroke — that patients with
stroke had no increase in survival due to t-PA and that
each patient would require 15 years of institutional
care — increased the cost-effectiveness ratio only mod-
erately (to $42,400), because these costs were incurred
by only 1 patient per 1000 receiving t-PA.
Subgroup Analyses
As is true of the main GUSTO study, our subgroup
analyses should be interpreted cautiously.1 For most of
the eight subgroups we studied, defined on the basis of
age and location of the infarction, the cost-effectiveness
ratio was below our benchmark figure of $50,000 per
year of life saved. The cost-effectiveness ratios were
least favorable for patients 40 years of age or younger
and for patients 60 years of age or younger with inferi-
or-wall infarctions, since these groups had the lowest
one-year mortality rates and the smallest increases in
survival due to treatment with t-PA.26 In our study, we
calculated the life expectancies of treated subgroups on
the basis of our survival model, rather than on short-
term empirical data for each subgroup. This technique
provided more stable and consistent estimates than the
alternative approach and also allowed us to control for
the fact that anterior myocardial infarction was more
frequent in older patients.
Conclusions
The routine substitution of accelerated t-PA for
streptokinase in the treatment of the approximately
250,000 eligible patients who have acute myocardial in-
farction in the United States each year would be cost
effective by customary criteria. It would cost the nation
approximately $500 million each year but would also
provide 3.5 million additional years of life for patients
after myocardial infarction. Our analysis can inform
the decision about whether this should become the
standard of care in the United States, but society itself
must make the choice.
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the present study would not have been possible; to Dr. Stephen Pauk-
er for his editorial assistance; to Julia Burchett and Celia Hybels for
data-collection support; to Linda Davidson-Ray for assistance in de-
veloping the cost data; to the GUSTO Steering Committee for their
review of the manuscript and their useful suggestions; and to Maria
Lee and Serena Smith for assistance in the preparation of the manu-
script.
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